Coronary artery disease Circulatory System Coronary artery disease
Conditions
Interventions
In brief all patients will be undergoing drug eluting intracoronary stent deployment as clinically indicated. Patients will be randomly allocated to receive a Yukon (rapamicin eluting polymer free) or
Sponsors
Royal Brompton and Harefield NHS Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age 18-75 2. Stable or unstable angina, Non-ST Elevation Myocardial Infarction (NSTEMI) but not ST-Elevation Myocardial Infarction (STEMI; primary Percutaneous Coronary Intervention (PCI) or rescue angioplasty) who have been pain-free for > 24h 3. Single or multiple lesions in a native coronary artery 4. 50-99% diameter stenosis 5. Lesion length 8-28mm (visually estimated) 6. Vessel diameter 2.5-3.5mm (visually estimated)
Exclusion criteria
Exclusion criteria: 1. Unprotected left mainstem lesion 2. Ostial lesion 3. Bifurcation lesion requiring side branch intervention 4. Severely calcified lesion that cannot be successfully pre-dilated 5. Marked tortuosity or angulation of target vessel 6. STEMI 7. Left Ventricular (LV) ejection fraction 200 µmol/L
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of binary stent strut coverage between the Yukon (rapamicin eluting polymer free) and Cypher (rapamicin eluting polymer coated) groups at 90 day optical coherence tomography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of mean neointimal thickness between the Yukon (rapamicin eluting polymer free) and Cypher (rapamicin eluting polymer coated) groups at 90 day optical coherence tomography. | — |
Countries
United Kingdom
Outcome results
None listed